Open
臨床階段生物製藥公司,專(zhuān)注非小細(xì)胞肺癌(NSCLC)新藥研究,ABT-101已獲得美國(guó)和臺(tái)灣FDA的研究性新藥(IND)應(yīng)用批準(zhǔn)。
Anbogen Therapeutics (ABT) is a clinical stage biopharmaceutical company founded in 2019, focusing on discovering and developing precision medicine in oncology.
Anbogen Therapeutics (ABT) is a clinical stage biopharmaceutical company founded in 2019, focusing on discovering and developing precision medicine in oncology.